Coagulation Factor XIII - Last to think about?

Abstract

This commentary thoroughly examines extensive bleeding, evaluating the current knowledge and analyzing whether earlier administration of coagulation factor XIII (FXIII) could be beneficial. The timely administration of FXIII is advised in managing massive bleeding to enhance clot stability, reduce the risk of rebleeding, and improve overall patient outcomes. While FXIII may not always be the first factor considered in the initial stages of bleeding management, its early administration can significantly prevent further bleeding complications and support adequate hemostasis in critically ill patients. Although this concept is initially intuitive, more solid scientific evidence is needed to support or indicate the optimal time point for the therapy with FXIII.